Abstract
Purpose
To evaluate intravesical paclitaxel monotherapy and combined treatment with antiapoptotic bcl-xL antisense oligodeoxynucleotides (AS-ODNs) on urothelial carcinoma (UC).
Methods
Forty-eight FoxNrnu athymic nude rats with orthotopic human bladder UC were randomized to four treatment groups [1, paclitaxel; 2, paclitaxel/bcl-xL AS-ODNs; 3, bcl-xL AS-ODNs (control); 4, medium (control)]. Three consecutive instillations were applied and weekly endoscopic tumor size measurements were performed.
Results
Significant tumor size reduction was achieved in groups 1 and 2 (each P < 0.0001), whereas continuous UC growth was observed in control animals (groups 3 and 4; P < 0.0001 and P < 0.0020). Complete tumor eradication was achieved in four treated animals (groups 1 and 2). No significant difference in chemoresection effects was found between groups 1 and 2 (P = 0.2251).
Conclusions
We present an in vivo evaluation of intravesical treatment with paclitaxel and combined bcl-xL AS-ODNs. Despite efficient tumor size reduction, no gain was observed when adding bcl-xL AS-ODNs in this experimental setting.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Au JL, Kalns J, Gan Y, Wientjes MG (1997) Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 41:69–74. doi:10.1007/s002800050709
Bolenz C, Becker A, Trojan L, Schaaf A, Cao Y, Weiss C et al (2007a) Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. Urol Oncol 25:476–482. doi:10.1016/j.urolonc.2007.01.017
Bolenz C, Wenzel M, Cao Y, Trojan L, Hacker A, Arancibia MF et al (2007b) Newly developed mini-endoscope for diagnosis and follow-up of orthotopic bladder transitional-cell carcinoma in vivo. J Endourol 21:789–794. doi:10.1089/end.2006.0355
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21:1315–1330. doi:10.2165/00019053-200321180-00003
Duggan BJ, Gray S, Johnston SR, Williamson K, Miyaki H, Gleave M (2002) The role of antisense oligonucleotides in the treatment of bladder cancer. Urol Res 30:137–147. doi:10.1007/s00240-002-0248-3
Fuessel S, Meye A, Kraemer K, Kunze D, Hakenberg OW, Wirth MP (2007) Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma. Eur Urol 51:315–326. doi:10.1016/j.eururo.2006.07.045 discussion 326–317
Glackin AJ, Gray SB, Johnston SR, Duggan BJ, Williamson KE (2005) Antisense oligonucleotides in the treatment of bladder cancer. Expert Opin Biol Ther 5:67–77. doi:10.1517/14712598.5.1.67
Grossman HB, Wedemeyer G, Ren L, Wilson GN, Cox B (1986) Improved growth of human urothelial carcinoma cell cultures. J Urol 136:953–959
Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM et al (2008) Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int 101:1347–1355. doi:10.1111/j.1464-410X.2008.07571.x
Hickman JA (1996) Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921–926. doi:10.1016/0959-8049(96)00080-9
Hong JH, Lee E, Hong J, Shin YJ, Ahn H (2002) Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int 90:113–117. doi:10.1046/j.1464-410X.2002.02799.x
Hopkins-Donaldson S, Cathomas R, Simoes-Wust AP, Kurtz S, Belyanskaya L, Stahel RA et al (2003) Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 106:160–166. doi:10.1002/ijc.11209
Koga S, Kondo Y, Komata T, Kondo S (2001) Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther 8:654–658. doi:10.1038/sj.gt.3301449
Korkolopoulou P, Lazaris A, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P et al (2002) Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 41:274–283. doi:10.1016/S0302-2838(02)00003-9
Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y et al (2008) Antisense-mediated inhibition of surviving, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 32:1049–1056
Kyle AH, Huxham LA, Yeoman DM, Minchinton AI (2007) Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 13:2804–2810. doi:10.1158/1078-0432.CCR-06-1941
Le Visage C, Rioux-Leclercq N, Haller M, Breton P, Malavaud B, Leong K (2004) Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 171:1324–1329. doi:10.1097/01.ju.0000103922.12319.59
Lebedeva I, Raffo A, Rando R, Ojwang J, Cossum P, Stein CA (2001) Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 166:461–469. doi:10.1016/S0022-5347(05)65964-2
McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP et al (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075–3080. doi:10.1200/JCO.2005.03.1161
Meyn RE, Stephens LC, Milas L (1996) Programmed cell death and radioresistance. Cancer Metastasis Rev 15:119–131. doi:10.1007/BF00049491
Miyake H, Eto H, Hara I, So A, Li D, Gleave ME (2004) Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. J Urol 171:2477–2481. doi:10.1097/01.ju.0000118382.89456.f7
Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME (2005) Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 7:171–179. doi:10.1593/neo.04478
Miyashita T, Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151–157
Nativ O, Aronson M, Medalia O, Moldavsky T, Sabo E, Ringel I et al (1997) Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 70:297–301. doi:10.1002/(SICI)1097-0215(19970127)70:3<297::AID-IJC9>3.0.CO;2-S
Schaaf A, Sagi S, Langbein S, Trojan L, Alken P, Michel MS (2004) Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 22:188–192. doi:10.1016/j.urolonc.2004.01.010
Song D, Wientjes MG, Au JL (1997) Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285–292. doi:10.1007/s002800050660
Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190. doi:10.1097/01.ju.0000125486.92260.b2 quiz 2435
Sylvester RJ, Oosterlinck W, Witjes JA (2008) The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 53:709–719. doi:10.1016/j.eururo.2008.01.015
Yin JQ, Gao J, Shao R, Tian WN, Wang J, Wan Y (2003) siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J Exp Ther Oncol 3:194–204. doi:10.1046/j.1359-4117.2003.01092.x
Zhao Q, Zhou R, Temsamani J, Zhang Z, Roskey A, Agrawal S (1998) Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. Antisense Nucleic Acid Drug Dev 8:451–458
Acknowledgments
This work was supported by a grant from the H. W. & J. Hector Stiftung, Weinheim, Germany.
Conflict of interest statement
None of the contributing authors have any conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
C. Bolenz and C. Weiss contributed equally to this work.
Rights and permissions
About this article
Cite this article
Bolenz, C., Weiss, C., Wenzel, M. et al. In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma. J Cancer Res Clin Oncol 135, 679–686 (2009). https://doi.org/10.1007/s00432-008-0500-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0500-5